Acadia Pharmaceuticals (ACAD) Non Operating Income (2012 - 2026)

Acadia Pharmaceuticals' Non Operating Income history runs 15 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 1.95% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $31.9 million, a 14.44% increase from a year earlier, with the FY2025 full-year figure at $31.7 million, up 24.61% from the prior year.
• Non Operating Income slipped to $8.1 million in Q1 2026 per ACAD's latest filing, from $8.3 million in the prior quarter.
• Across five years, Non Operating Income topped out at $8.3 million in Q4 2025 and bottomed at $105000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $5.5 million (2024), against an average of $5.2 million.
• Across the five-year window, Non Operating Income slumped 47.5% in 2022 and jumped 3519.05% in 2023, its largest moves.
• Year by year, Non Operating Income stood at $3.6 million in 2022, then jumped by 31.1% to $4.8 million in 2023, then jumped by 47.24% to $7.0 million in 2024, then advanced by 18.91% to $8.3 million in 2025, then dropped by 3.32% to $8.1 million in 2026.
• Per Business Quant, the three latest ACAD Non Operating Income figures stand at $8.1 million (Q1 2026), $8.3 million (Q4 2025), and $8.2 million (Q3 2025).